Highlights

• Compumedics is a medical-technology company developing diagnostic solutions across sleep medicine, neurology, brain imaging and blood-flow monitoring.

• The company reported record FY2026 revenue of approximately A$60 million, supported by growth across its diagnostic technology portfolio.

• Recurring software revenue continues to become an important growth area, supported by platforms including Somfit and Nexus 360.

Compumedics (ASX:CMP) traded at A$0.22, down 8.33% during trading on 29 July 2026, as investors assessed the company’s latest financial performance, guidance outlook and growth initiatives.

The company operates across healthcare technology markets, providing diagnostic systems and software solutions for sleep disorders, neurological conditions and brain imaging applications.

Compumedics’ future performance remains linked to product execution, international expansion and the ability to convert technology development into consistent financial growth.

Compumedics’ recent market movement followed investor assessment of its FY2026 performance update, where the company reported record revenue but remained below its previously revised expectations. The company continues progressing its medical-device portfolio, with recurring software revenue growth providing a potential long-term earnings driver. Key focus areas include MEG system deliveries, the US Somfit rollout and future guidance.

Company overview: medical diagnostics and healthcare technology

Compumedics develops, manufactures and commercialises medical-device technologies across multiple healthcare segments.

The company’s operations include sleep diagnostics, neurology and neurodiagnostic systems, magnetoencephalography (MEG) brain imaging technology and ultrasonic blood-flow monitoring.

Compumedics operates internationally, including through its US neuroscience business and European operations.

The company has increasingly focused on building recurring software revenue streams alongside its hardware portfolio, improving the potential for more consistent revenue generation.

Explaining the share-price movement

Compumedics traded at A$0.22 during the trading session on 29 July 2026, down 8.33% on the day.

The movement followed investor reassessment of the company’s recent operational update, which highlighted record revenue growth while also reflecting timing challenges affecting certain product deliveries.

The market focus has centred on whether delayed MEG shipments and product launch timing issues can be resolved while maintaining growth momentum.

Investors are also monitoring whether recurring software revenue can improve earnings visibility over time.

Latest market information (as at 29 July 2026)

Compumedics (ASX:CMP):

  • Share price: A$0.22
  • Daily movement: Down 8.33%
  • 52-week high: Not provided
  • 52-week low: Not provided

Latest announcements and company developments

Compumedics’ recent update highlighted record FY2026 revenue performance while also identifying timing-related challenges.

The company reported that helium supply constraints affected MEG system shipment timing, while the rollout of its next-generation Somfit product in the United States progressed slower than expected.

The company continues focusing on expanding its diagnostic technology offering and growing recurring software revenue through platforms such as Somfit and Nexus 360.

Most recently reported financial performance

Compumedics reported preliminary FY2026 revenue of approximately A$60 million, representing record annual revenue for the company.

The half-year period ended 31 December 2025 showed revenue of approximately A$31 million, supported by growth across its healthcare technology operations.

During the same period, the company returned to a small net profit of approximately A$0.3 million and reported EBITDA of around A$3.1 million.

For FY2025, Compumedics reported revenue of approximately A$51 million.

The company’s financial performance reflects ongoing investment in product development, international operations and technology expansion.

Major products and growth initiatives

Sleep Diagnostics Platform

Sleep diagnostics remains an important part of Compumedics’ business.

The company’s Somfit platform is designed to support home-based sleep monitoring, aligning with broader healthcare trends toward remote and decentralised diagnostics.

The US market represents a significant opportunity, with future growth dependent on product rollout, regulatory progress and commercial adoption.

MEG Brain Imaging Technology

Compumedics’ MEG systems provide advanced brain-imaging capabilities used in neuroscience research and clinical applications.

These systems are high-value products, although sales timing can vary due to installation requirements, supply conditions and customer purchasing cycles.

Nexus 360 Software

Recurring software revenue has become an increasingly important component of the company’s strategy.

Platforms such as Nexus 360 support healthcare workflows and provide potential for more predictable revenue streams.

Industry and market context

Compumedics operates within healthcare technology markets supported by long-term trends including ageing populations, increasing demand for neurological diagnostics and growth in home-based healthcare monitoring.

Medical-device companies face challenges including regulatory requirements, product adoption cycles and supply-chain constraints.

For Compumedics, the opportunity lies in combining established diagnostic hardware with scalable software solutions.

Potential catalysts investors may monitor

FY2027 guidance:
Future guidance will provide insight into growth expectations following recent timing challenges.

MEG system deliveries:
Improved shipment timing could support revenue recognition and operating performance.

US Somfit rollout:
Successful expansion could strengthen the company’s sleep diagnostics presence.

Recurring software growth:
Increasing SaaS revenue could improve earnings quality and revenue visibility.

Material company-specific risks

Guidance execution risk:
Meeting future expectations remains important after recent timing challenges.

Supply-chain risk:
Availability of components and specialised inputs can affect delivery schedules.

Product launch risk:
Delays in new product adoption may affect revenue growth.

International operations risk:
Global operations expose the company to currency and regional market factors.

Healthcare regulation risk:
Medical-device approvals and compliance requirements can affect commercial timelines.

Balanced outlook

Compumedics combines an established medical-device portfolio with emerging software-driven growth opportunities.

The company’s technology platform provides exposure to healthcare trends including sleep diagnostics, neuroscience and remote monitoring.

The key challenge remains converting technology capability into consistent financial performance while managing product timing and market expansion.

Future progress will depend on successful product launches, recurring revenue growth and improved earnings visibility.

Conclusion

Compumedics continues developing its healthcare technology platform across diagnostics, neuroscience and software solutions.

The company’s recent market movement reflects investor assessment of operational execution, guidance delivery and future growth opportunities.

Key areas to monitor include MEG shipment timing, Somfit expansion, recurring software revenue growth and future financial guidance.